Fresenius Medical Care named Korangy CEO. FMC stock sits 20.87 percent below its high

Published on 10/12/2026 at 09:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Korangy, 51, starts on October 12, 2026 after a unanimous vote. FMC stock costs EUR 37.87 on October 12, 2026, 20.87 percent below EUR 47.86.

Key points in brief

Shervin Korangy took over as FMC CEO on October 12, 2026, succeeding Helen Giza.
FMC reported EUR 4.861 billion in second-quarter 2026 revenue and EUR 569.0 million in adjusted operating income.
FMC stock was at EUR 37.87 at Lang & Schwarz on October 12, 2026, 20.87 percent below its 52-week high of EUR 47.86.
FMC's investor calendar lists November 3, 2026, for third-quarter results.

3D-Architekturrender eines modernen Glas- und Stahlgebäudes mit begrüntem Vorplatz — Architektur-Render zeigt modernes Glasgebäude als Sinnbild für Fresenius Medical Care AG DE0005785802 mit minimalistischer Fassade, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) named Shervin J. Korangy as its new CEO effective October 12, 2026. At EUR 37.87, FMC stock was 20.87 percent below its 52-week high of EUR 47.86 at Lang & Schwarz on October 12, 2026 at 9:13 a.m. CEST.

Three events shaped the stock

On August 3, 2026, Fresenius Medical Care reported second-quarter revenue of EUR 4.861 billion and adjusted operating income of EUR 569.0 million, up 20.00 percent from EUR 476.0 million in the prior-year quarter, according to EuropeSays.

On September 25, 2026, PR Newswire reported that FMC would exit its China peritoneal dialysis business and discontinue local production and sales of the 4008A system, with the charge expected in the third quarter of 2026.

On October 7, 2026, Fresenius Medical Care said the 51-year-old Korangy would succeed Helen Giza after a unanimous supervisory board decision.

What does the leadership change mean?

The appointment puts operational continuity against a demanding financial backdrop. In the second quarter of 2026, revenue rose 1.44 percent from EUR 4.792 billion, while adjusted operating income increased 20.00 percent from EUR 476.0 million to EUR 569.0 million, according to EuropeSays.

That contrast matters because the company is changing leadership while its transformation program is still contributing to profitability. The China strategy adds a separate execution issue, with the affected market representing 6-7 percent of Care Enablement revenue, according to PR Newswire.

Next dates are already set

Fresenius Medical Care's investor calendar lists third-quarter 2026 reporting for November 3, 2026 and the quarterly financial report for November 6, 2026, according to Fresenius Medical Care. Those dates give the market a defined checkpoint for Korangy's first weeks as CEO.

FMC stock stays below its yearly high

FMC stock was trading at EUR 37.87 at Lang & Schwarz on October 12, 2026 at 9:13 a.m. CEST, up EUR 0.37 or 0.99 percent versus the Xetra close of October 9, 2026 at EUR 37.50. The quote sat within a 52-week range of EUR 34.57 to EUR 47.86, while market capitalization stood at EUR 10.1 billion as of October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of FMC stock.